Overview

A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-12

Target enrollment:

Participant gender:

Summary

Comparison of MODIFIED progression-free survival (Modified-PFS) in high-dose rituximab (500mg/m²) plus CHOP versus standard-dose rituximab plus CHOP in previously untreated (TN) stage III-IV male DLBCL patients

Phase:

PHASE3

Details

Lead Sponsor:

Xia Yi

Treatments:

Rituximab